Chicago-The diagnosis and treatment of inflammatory glaucoma remain one of the most challenging problems for ophthalmologists, according to Chicago glaucoma specialist Jon M. Ruderman, MD.
Alameda, CA-The U.S. Patent & Trademark Office said InSite Vision Inc.'s patent gives the company sole rights to the use of azalide antibiotic formulations as a topical treatment of ocular infections.
Orlando-Children with moderate amblyopia may be successfully treated with patching or atropine drops, regardless of age less than 7 years or depth of amblyopia for the most common causes of amblyopia, according to Michael X. Repka, MD, at the American Academy of Ophthalmology annual meeting.
Andover, MA-The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day of treatment and 90% by 7 to 9 days, according to a phase II clinical trial.
Indianapolis-Preoperative povidone-iodine antisepsis showed the strongest support in the literature for preventing bacterial endophthalmitis in patients undergoing cataract surgery. However, that recommendation was judged to be only "moderately important" to clinical outcome, based on the quality of the available evidence. The review failed to find that any technique was crucial to clinical outcome, said Thomas A. Ciulla, MD.
Boston-Multiple intravitreal injections of rhuFab V2 (Genentech Inc., San Francisco) are well-tolerated and appear to have favorable biologic activity for the treatment of exudative age-related macular degeneration (AMD), said Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston and the Center for Eye Research, principal investigator for that trial.
The creation of a mobile ophthalmologic aid service in Russia has enabled elderly and disabled patients access to desperately needed eye care.
Baltimore-Researchers are working to improve their understanding of the cascade of events that lead to retinal degeneration and vision loss. This active research could lead eventually to clinical treatments, according to Jennifer Sung, MD, who spoke at the Current Concepts in Ophthalmology Meeting here.
Baltimore-Ophthalmologists can now use new guidelines on how best to treat optic neuritis based on the results from the Optic Neuritis Treatment Trial (ONTT), which followed long-term outcomes for 10 years, according to Neil R. Miller, MD, who spoke at the Current Concepts in Ophthalmology Meeting.
Baltimore-Macular edema is the final common pathway for visual loss in many diseases, but so far, available treatments have not been effective in improving visual acuity to 20/20 in a significant percentage of patients, according to Julia A. Haller, MD, who spoke during the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine, here.